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Purpose: Combinations of long-acting bronchodilators are recommended to reduce the rate 
of COPD exacerbations. Evidence from the DYNAGITO trial showed that the fixed-dose 
combination of tiotropium + olodaterol reduced the annual rate of total exacerbations (P,0.05) 
compared with tiotropium monotherapy. This study aimed to estimate the cost-effectiveness 
of the fixed-dose combination of tiotropium + olodaterol vs tiotropium monotherapy in COPD 
patients in the French setting.
Patients and methods: A recently developed COPD patient-level simulation model was 
used to simulate the lifetime effects and costs for 15,000 patients receiving either tiotropium + 
olodaterol or tiotropium monotherapy by applying the reduction in annual exacerbation rate as 
observed in the DYNAGITO trial. The model was adapted to the French setting by including 
French unit costs for treatment medication, COPD maintenance treatment, COPD exacerbations 
(moderate or severe), and pneumonia. The main outcomes were the annual (severe) exacerbation 
rate, the number of quality-adjusted life-years (QALYs), and total lifetime costs.
Results: The number of QALYs for treatment with tiotropium + olodaterol was 0.042 higher 
compared with tiotropium monotherapy. Using a societal perspective, tiotropium + olodaterol 
resulted in a cost increase of +€123 and an incremental cost-effectiveness ratio (ICER) of €2,900 
per QALY compared with tiotropium monotherapy. From a French National Sickness Fund 
perspective, total lifetime costs were reduced by €272 with tiotropium + olodaterol, resulting 
in tiotropium + olodaterol being the dominant treatment option, that is, more effects with less 
costs. Sensitivity analyses showed that reducing the cost of exacerbations by 34% increased the 
ICER to €15,400, which could still be considered cost-effective in the French setting.
Conclusion: Treatment with tiotropium + olodaterol resulted in a gain in QALYs and savings 
in costs compared with tiotropium monotherapy using a National Sickness Fund perspective in 
France. From the societal perspective, tiotropium + olodaterol was found to be cost-effective 
with a low cost per QALY.
Keywords: COPD, tiotropium, olodaterol, exacerbations, modeling, QALYs, costs
Introduction
Pharmaceutical treatment options for COPD focus on 1) reducing respiratory symptoms 
and the frequency and severity of exacerbations and 2) improving exercise tolerance 
and health status.1 The pharmacologic therapy for moderate-to-severe COPD usu-
ally includes long-acting bronchodilators, that is, long-acting β2-agonists (LABAs) 
or long-acting muscarinic antagonists (LAMAs). A combination of two long-acting 
bronchodilators (LABA + LAMA) is recommended for patients with persistent or 
severe dyspnea, or with a high risk for exacerbations. Inhaled corticosteroids (ICS) 
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and antibiotics can be used to treat and mitigate the effects 
of exacerbations.1,2 Overall, bronchodilation using a LAMA 
alone or in combination with a LABA is recommended for a 
large group of patients regardless of their COPD phenotype.
The fixed dose LABA/LAMA combination of once daily 
orally inhaled tiotropium + olodaterol (5/5 µg) was found to 
have increased effectiveness with respect to lung function, 
physical functioning, and health-related quality of life com-
pared with its mono-components.3–5 Recently, the impact of 
tiotropium + olodaterol on the annual rate of exacerbations 
was investigated in the DYNAGITO trial. This trial was a 
52-week multi-national double-blind trial investigating the 
impact of once daily orally inhaled tiotropium + olodaterol 
(LAMA + LABA) (5/5 µg) compared with tiotropium 
monotherapy (5 µg) (LAMA) on the rate of exacerbations 
in patients with a history of exacerbations and a FEV
1
% pre-
dicted below 60%.6 The trial showed that the annual rate of 
total exacerbations was reduced in the tiotropium + olodaterol 
arm, 0.90, compared with the tiotropium monotherapy arm, 
0.97 (rate ratio [RR]: 0.93 [P-value 0.0498]). The annual 
rate for severe exacerbations defined as a hospitalization was 
lower in the combination arm, 0.18, compared with 0.20 for 
the tiotropium arm, but this difference was not statistically 
significant (RR: 0.89 [95% CI: 0.76 to 1.03]).
Besides investigating the effectiveness of tiotropium + 
olodaterol compared with tiotropium monotherapy, it is also 
important to assess at what costs these additional effects 
are obtained. Given the continuously increasing health care 
expenditures, especially for medication, cost-effectiveness 
(CE) information becomes increasingly important to guide 
reimbursement decisions and clinical guideline development. 
Therefore, the aim of this study was to estimate the long-term 
CE of tiotropium + olodaterol vs tiotropium monotherapy 
in a French health care setting by applying the reduction in 
exacerbations observed in the DYNAGITO trial in a recently 
developed COPD CE model.7
Materials and methods
Model structure
The patient-level discrete event simulation model used 
for the analysis has recently been developed and has been 
described in detail elsewhere.7 The model is unique because 
none of the previously developed health economic models 
for COPD included such a wide range of different patient 
characteristics and outcomes. Patient and disease character-
istics included in the model are sex, age, body mass index 
(BMI), smoking status, number of pack-years, history of 
heart failure, other cardiovascular disease, asthma, diabetes 
and depression, bronchodilator responsiveness, presence of 
emphysema, eosinophil level, and use of ICS. These charac-
teristics were assumed to influence the intermediate and final 
outcomes. Intermediate outcomes included in the model are 
exacerbations, pneumonia, lung function, exercise capacity, 
physical activity, symptoms, and disease-specific quality of 
life. Final outcomes are mortality, the number of quality-
adjusted life-years (QALYs), and costs. The model consists 
of a series of consecutive regression equations describing 
the statistical associations between the aforementioned 
patient characteristics and changes in intermediate and final 
outcomes over time. These equations were estimated using 
the longitudinal, patient-level data of five large COPD trials 
evaluating tiotropium (UPLIFT, EXACTT, POET, TIOSPIR, 
and TONADO).3,8–11 Since only data from patients included 
in the tiotropium arms of the trials were used to estimate the 
regression equations, the outcomes of the equations are con-
sidered to reflect treatment with tiotropium. Starting point of 
the simulation is the baseline patient population of the same 
five large COPD trials evaluating tiotropium.3,8–11 The model 
then randomly samples one patient (with replacement). By 
filling in the patients’ characteristics into the time-to-event 
regression equations, the time-to-exacerbation, pneumonia, 
and death are calculated. The event with the lowest predicted 
value (time) is assumed to happen first and intermediate out-
comes, that is, lung function, exercise capacity, physical activ-
ity, symptoms, and disease-specific quality of life are updated 
at the time of the event by filling in the time passed and the 
(updated) patient and disease characteristics in the equations 
for outcomes. New times to events are then calculated using 
the updated values for the intermediate outcomes and the 
process is repeated again. Intermediate and final outcomes are 
updated every time an event occurs. The simulation continues 
until the patient dies, which occurs when the predicted event 
to happen first is death. Intermediate and final outcomes are 
also updated when a year has passed without event to avoid 
having few observations for patients with a low frequency of 
events. The process is repeated by randomly drawing multiple 
patients and simulating their individual disease progression 
over time until the moment of death. By combining the data 
of all simulated patients, the average change in intermediate 
and final outcomes is calculated. The standard time horizon 
of the model is lifetime and the model has been implemented 
in R using the software RStudio (version 1.1.383).
selected model population
The model can be used to simulate results for a wide variety 
of subgroups by randomly sampling from the subgroup of 
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interest in the total baseline patient population of the model. 
For the current analyses, we selected the subset of patients 
that met the DYNAGITO trial-specific inclusion criteria, 
that is, a post-bronchodilator FEV
1
% predicted to be ,60% 
and a history of at least one exacerbation in the 12 months 
before the trial.6 Other inclusion criteria of the DYNAGITO 
trial were also applied to sample a starting population that 
was similar to that in the trial.
Treatment scenario
Different intervention scenarios can be simulated with 
the model by applying different treatment effects. In the 
current study, we applied the rate ratios (RRs) as found in 
the DYNAGITO trial, of 0.93 and 0.89 for total and severe 
exacerbations, respectively.6 Because in the model, the risk 
of an exacerbation has been implemented as a time-to-event 
equation and not as an annual exacerbation risk, the time to 
exacerbation was calibrated by increasing it with a certain 
factor (about 8% increase). This factor was chosen such 
that the RR of exacerbations in the tiotropium + olodaterol 
group compared with the tiotropium-only group was 0.93. 
In addition, the outcome of the equation predicting the prob-
ability that an exacerbation is severe was adapted (about 
4% reduction) in such a way that the model outcomes for 
severe exacerbations for the first year matched the RR of 
0.89 observed in the DYNAGITO trial. The model was run 
for a life-time time horizon for 15,000 patients, assuming the 
DYNAGITO treatment effects are permanent and constant 
over time. In the comparator group reflecting treatment with 
tiotropium monotherapy, no changes were made to the model 
equations. According to the French guidelines for economic 
evaluation from HAS, costs and effects were discounted at 
4% in the first 30 years and at 2% thereafter.12
Perspective
The CE study for the French setting was performed from 
two different perspectives. The National Sickness Fund 
perspective considered all health care-related costs that are 
reimbursed by the National Healthcare insurance and the cost 
of daily allowances paid to the patient when on sick leave. 
The societal perspective considered all health care costs that 
are reimbursed by both public and private insurance, patient 
co-payments for medication (non-reimbursed costs), and 
costs of productivity loss related to absence from paid work.
resource use and costs
The model distinguishes between costs related to the use of 
study medication, for maintenance treatment, for exacerba-
tions and for treatment of pneumonia. All health care use 
was valued in euros (€) using unit costs from the year 2016 
(Table 1).13–18 Costs related to study medication consisted 
of costs for either tiotropium + olodaterol or tiotropium 
monotherapy and were calculated as the number of days alive 
multiplied with the medication costs per day.13 Drug acqui-
sition costs dispensed in retail pharmacies were taken from 
official list prices. Dispensing fees, reimbursement rates, 
and percentages of long-term illness have been considered 
for the medication costs per day.
Maintenance treatment included visits to primary and sec-
ondary care physicians, number of spirometries, use of influ-
enza vaccinations, and use of ICS (Table 1). Based on two 
regression equations, the model predicts the annual number 
of visits to the general practitioner (GP) and the respiratory 
specialist using all baseline patient characteristics and inter-
mediate outcomes as predictors. The outcome of the equa-
tions, that is, the predicted number of visits, was multiplied 
with a country-specific correction factor to make the resulting 
Table 1 COPD-related health care use and unit costs for maintenance treatment for France
Maintenance costs Country-specific 
annual mean
Non-country-specific 
annual mean
Unit costs
(National Sickness 
Fund perspective)
Unit costs
(societal 
perspective)
References
Treatment medication
Tiotropium + olodaterol – – €1.30 per day €1.60 per day 13
Tiotropium – – €0.92 per day €1.01 per day 13
Visits + other medication
Primary care visits (gP) 8.8 equation in the model €23.19 per visit €26.07 per visit 14, 15
specialist visits 1.1 equation in the model €52.05 per visit €59.04 per visit 15, 16
spirometries 1.4 – €37.01 per spirometry €41.57 per spirometry 16, 17
Influenza vaccination (%) 50.4% – €6.10 per vaccination €6.10 per vaccination 13, 18
ICs use – number of days alive 
if ICs at baseline
€1.17 per day €1.30 per day 13
Abbreviations: –, not applicable; gP, general practitioner; ICs, inhaled corticosteroids.
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number of visits representative for the country of interest. 
This correction factor was calculated as the average number 
of COPD-related visits among COPD patients in a specific 
country divided by the average number of COPD-related 
visits among COPD patients predicted by the equation. 
In France, the mean annual number of COPD-related visits 
in patients with COPD was 8.8 for the GP and 1.1 for the 
respiratory specialist in patients with COPD.14,16 The doctor’s 
fees have been calculated using open data from the National 
Health care Insurance database (DAMIR).15 The number 
of spirometries and the use of influenza vaccinations were 
assumed constant for all patients in the model and based 
on a study by Laurendeau et al and the guidelines from 
Jebrak.16,18 For all patients using ICS at baseline, cost of ICS 
was calculated by multiplying the number of days alive with 
the medication cost per day.13
Costs of exacerbations were specified separately for 
moderate and severe exacerbations. A moderate exacerba-
tion was defined as an increase in respiratory symptoms 
requiring a visit to health care provider and treatment with 
antibiotics and/or oral steroids, whereas a severe exacerbation 
was defined as an increase in respiratory symptoms resulting 
in hospitalization. A study of Laurendeau et al16 estimated 
the costs of moderate and severe exacerbation in France 
(Table 2), which were also used in previous cost analysis.19 
Costs were specified for the National Sickness Fund and the 
societal perspectives below and above the age of 62 years, 
which is the mean retirement age in France.20 The mean 
number of working days lost in relation to a moderate and 
severe exacerbation for patients below the retirement age 
were based on the POET trial10 and were estimated to be 1.73 
and 4.82, respectively. These numbers were calculated while 
taking into account that for a large part of the exacerbations, 
there was no productivity loss, because patients did not have 
a paid job anymore or the exacerbations had no impact on 
productivity. Costs related to productivity loss were calcu-
lated by multiplying the mean number of work days lost with 
the average wages per day in France.21–24 Costs of pneumonia 
with and without hospitalization were assumed to be the same 
as the costs for a moderate and severe exacerbation. This was 
done because the number of pneumonia in the model was 
very low and experts indicated that treatment for pneumonia 
did not differ much from the treatment for exacerbations.
health outcomes
The model includes a wide variety of health outcomes: 
number of (severe) exacerbations, number of pneumonia, 
decline in lung function (FEV
1
 in mL per year), exercise 
capacity (treadmill test in seconds), physical activity level 
(St George’s Respiratory Questionnaire (SGRQ) sub-score 
for activity (range 0–100)), presence of symptoms (breath-
lessness and cough/sputum), disease-specific quality of life 
(SGRQ total score, range 0–100), remaining life-expectancy 
since start of the simulation (in years), and QALYs. For 
the current CE analysis, the main outcome of interest 
was the difference in QALYs between treatment with 
tiotropium + olodaterol and tiotropium monotherapy. The 
number of QALYs was calculated as the mean value of the 
utility value at start and end of a time period multiplied with 
the duration of the time period. Utility values at different 
time points were derived from the SGRQ total score using a 
previously published mapping algorithm.25
Cost-effectiveness
The incremental cost-effectiveness ratio (ICER) was calcu-
lated as the difference in the total average lifetime costs per 
patient between treatment with tiotropium + olodaterol and 
treatment with tiotropium monotherapy divided by the differ-
ence in the average number of QALYs per patient between 
the two treatments options.
sensitivity analyses (sa)
Several one-way SA were performed on discount rate, time 
horizon, percentage of ICS users at baseline, and the cost 
estimates of exacerbations used in the analysis. For the 
first SA, results were calculated without discounting, while 
the second SA explored the impact of using a shorter time 
horizon, that is, 5 years. The percentage of patients using 
ICS was slightly different in the sampled patient popula-
tion from the model (63%) compared with the DYNAGITO 
Table 2 exacerbation costs in France
Total costs Moderate 
exacerbation
Severe 
exacerbation
national sickness Fund perspective 
(below retirement age of 62 years)
€801 €7,504a
national sickness Fund perspective
(above retirement age of 62 years)
€801 €7,438
societal perspective
(below retirement age of 62 years)
€1,341b €9,362c
societal perspective
(above retirement age of 62 years)
€866 €8,037
Notes: Data from laurendeau et al.16 aCosts from laurendeau et al’s study + (4.81–3 
first days not paid=) 1.81 × daily allowances of €36.45 per day. bsocietal costs based 
on laurendeau et al’s study + productivity loss as observed in the POeT trial (1.73 
days lost for a moderate exacerbation) multiplied with the costs of one day lost, 
€274.80.22,23 csocietal costs based on laurendeau et al’s study + productivity loss as 
observed in the POeT trial (4.82 days lost for severe exacerbation), multiplied with 
the costs of 1 day lost, €274.80.22,23
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trial (70%). Consequently, a third SA was done using a 
patient population at the start of the model simulation with 
the same distribution of ICS users as observed in the trial, 
which was achieved by using weighted sampling. The study 
of Laurendeau et al16 reported estimates of exacerbation cost 
that included both COPD and non-COPD-related costs, while 
the original model only included COPD-related costs. For the 
fourth SA, 34% lower estimates of the cost of a moderate 
and severe exacerbation were used to assess the impact of 
this difference. The factor of 34% was based on a study by 
Detournay et al presenting annual COPD-related costs and 
total costs among COPD patients showing that about 66% 
of the total costs were related to COPD.14 All SA were per-
formed using the societal perspective.
In addition, probabilistic SA (PSA) were done for the main 
analysis. Besides patient heterogeneity due to the variation in 
sampled patients at start of the simulation, the PSA included 
two types of uncertainty: 1) stochastic uncertainty, which is 
uncertainty related to drawing random values from probability 
distributions during the simulation and 2) parameter uncer-
tainty, which is uncertainty associated with the coefficients of 
the regression equations describing disease progression and 
the treatment effect parameters. The PSA was implemented 
as a double loop; an inner loop, in which a number of patients 
were sampled with replacement from the starting population 
of the model, and an outer loop in which values of the input 
parameters of the model were randomly drawn. For the current 
PSA, the model was run for 500 different sets of randomly 
drawn input parameters with a sample size of 100 patients per 
set, which was sufficient for the current analyses based on the 
paper of O’Hagan et al.26 For each set of randomly drawn coef-
ficients, the mean outcomes over 100 patients were recorded, 
and the mean and 2.5th and 97.5th percentiles (uncertainty 
interval [UI]) over all 500 mean values for each outcome were 
calculated. The 500 resulting differences in QALYs and in 
costs between treatment with tiotropium + olodaterol vs tiotro-
pium monotherapy were plotted in CE planes. A CE-plane is 
an x-y diagram with the x-axis representing the difference in 
QALYs between tiotropium + olodaterol vs tiotropium mono-
therapy and the y-axis representing the difference in costs. 
The information in the CE-plane is summarized in CE accept-
ability curves, which show the probability that treatment with 
tiotropium + olodaterol is cost-effective at several maximum 
willingness to pay values to gain one QALY.
Results
Table 3 shows the baseline characteristics of the sampled 
starting population for the model analysis and the patient 
population in the tiotropium arm of the DYNAGITO trial. 
The patient populations were comparable with respect to the 
mean FEV
1
, percentage of people with a low BMI, smoking 
status, percentage of patients experiencing previous exacer-
bations, and mean value for disease-specific quality of life. 
Small differences were found in the percentage of female 
patients (25% vs 28%), mean age (64 vs 66 years), and the 
number of pack-years (43 vs 45). The percentage of patients 
using ICS showed the greatest difference, 63% in the model 
vs 70% in the DYNAGITO trial. The impact of this difference 
on the outcomes was addressed in the SA.
For the first year of the simulation, the model predicted a 
total exacerbation rate of 0.805 per patient for treatment with 
tiotropium + olodaterol and 0.868 for treatment with tiotro-
pium monotherapy, resulting in an RR of 0.93. For severe 
exacerbations, the rates were 0.153 and 0.172, respectively, 
resulting in an RR of 0.89.
Table 4 shows the mean annual rates for total and severe 
exacerbations over lifetime. When comparing the two treat-
ment options, the RRs over lifetime were 0.92 for the annual 
rate of total exacerbations and 0.87 for the annual rate of 
severe exacerbations. Comparison of the other clinical out-
comes between the two treatment options showed that the 
remaining life-expectancy since start of the simulation was 
0.1 year higher for treatment with tiotropium + olodaterol. 
Other clinical outcomes also improved but the improvements 
were very small (Table 4).
Compared with tiotropium monotherapy, treatment 
with tiotropium + olodaterol resulted in a QALY gain 
Table 3 Baseline characteristics of the 15,000 simulated patients 
of the model compared with the patients who participated in the 
DYnagITO trial
Model  
(15,000 sampled 
patients)
DYNAGITO 
trial (tiotropium 
arm)
Female, % 25.4 27.9
age (years) 64.0 66.3
FeV1 (l) 1.19 1.20
FeV1% predicted 42 44
low BMI (,21 kg/m2), % 18.1 18.3a
Smokers, % 37.7 37.5
Pack-years 42.8 44.7
ICS users, % 62.8 70.1
severe exacerbations in 
previous year, %
28.7 27.4
sgrQ total score (points) 47.5 47.4
Note: aapproximated based on the mean BMI + sD.
Abbreviations: BMI, body mass index; ICs, inhaled corticosteroid; sgrQ, st george’s 
respiratory Questionnaire.
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of 0.042 (PSA: 0.043 [95% UI: -0.015 to 0.102]). From 
the National Sickness Fund perspective, treatment costs 
were €1,060 higher for tiotropium + olodaterol. However, 
these higher costs were compensated by the reduction in 
exacerbation costs of €1,355. As a result, treatment with 
tiotropium + olodaterol resulted in €272 lower (PSA: -€267 
[95% UI: -€1,318 to €533]) total lifetime costs compared 
with tiotropium monotherapy. From a National Sickness 
Fund perspective, tiotropium + olodaterol was the dominant 
treatment option, that is, it showed a gain in QALYs and less 
costs. From the societal perspective, the higher treatment 
medication costs for tiotropium + olodaterol compared with 
tiotropium (€1,643) were not completely offset by the reduc-
tion in exacerbation costs (€1,540) (Figure 1).
As a result, total lifetime costs from the societal per-
spective were €123 higher (PSA: €131 [95% UI: -€1,021 
to €1,026]) for tiotropium + olodaterol compared with 
tiotropium monotherapy resulting in an ICER of €2,900 per 
QALY gained. From the societal perspective, the CE-plane 
for the analysis (Figure 2) showed that in 93% of the PSA 
model simulations, tiotropium + olodaterol resulted in a 
gain in QALYs compared with tiotropium monotherapy, 
while in 35%, it resulted in cost savings. From the National 
Sickness Fund perspective, these values were 93% and 73%, 
respectively.
The acceptability curve for the societal perspective 
(Figure 3) showed that, the probability that treatment 
with tiotropium + olodaterol is cost-effective at different 
Table 4 lifetime model results for treatment with tiotropium + olodaterol vs with tiotropium monotherapy
Tiotropium + 
olodaterol
Tiotropium
severe exacerbation rate per year 0.163 0.187
Total exacerbation rate per year 0.724 0.786
Pneumonia per year 0.039 0.040
remaining life-expectancy since start of the simulation (years) 9.94 9.84
annual decline in lung function (ml) -38.3 -38.3
annual change in exercise capacity (seconds) -4.4 -4.6
annual change in physical activity (sgrQ activity score in points) +1.52 +1.53
Percentage of time periods with cough/sputum, % 66.1 66.2
Percentage of time periods with breathlessness, % 70.5 70.9
Annual change in disease-specific quality of life (SGRQ total score in points) +1.03 +1.04
Total number of QalYs (discounted) 4.80 4.76
Total lifetime costs from the national sickness Fund perspective (discounted) €22,161 €22,433
Total lifetime costs from the societal perspective (discounted) €25,606 €25,483
Abbreviations: QalYs, quality-adjusted life-years; sgrQ, st george’s respiratory Questionnaire.
Figure 1 Lifetime costs per patient specified by category for treatment with 
tiotropium + olodaterol (black bars) vs tiotropium monotherapy (gray bars) 
(discounted costs from the societal perspective).
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Figure 2 Ce plane for tiotropium + olodaterol vs tiotropium monotherapy based 
on discounted costs from the societal perspective.
Abbreviations: Ce, cost-effectiveness; QalYs, quality-adjusted life-years.
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willingness to pay thresholds of €10,000, €20,000, and 
€40,000 per QALY was 73%, 85%, and 92%, respectively. 
For the National Sickness Fund perspective, these values 
were 92%, 96%, and 96%, respectively.
Figure 4 shows the results of the SA using the societal 
perspective. All analyses resulted in a gain in QALYs and 
higher costs for tiotropium + olodaterol. No discounting and 
using a higher percentage of ICS users resulted in a reduc-
tion of the cost per QALY gained, while using a shorter time 
horizon and using 34% lower cost estimates for exacerbations 
resulted in a slight increase of the ICER to €15,400/QALY, 
which could still be considered cost-effective in the French 
setting.
Discussion
The current study aimed to estimate the CE of the fixed dose 
combination of tiotropium + olodaterol vs tiotropium mono-
therapy in the French setting using the effectiveness results 
of the DYNAGITO trial, which demonstrated a lower rate of 
moderate-to-severe exacerbations compared with tiotropium 
monotherapy. The relative risk for exacerbations found in this 
trial was the main driver of the results. Exacerbation preven-
tion is an important goal in the management of COPD and CE 
of interventions is highly dependent on the ability to prevent 
exacerbations, particularly, severe exacerbations that impact 
cost and health outcomes the most. In the current CE analy-
sis, treatment with tiotropium + olodaterol was found to be 
cost-effective when compared with tiotropium monotherapy. 
From the societal perspective, treatment with tiotropium + 
olodaterol is associated with a low ICER of €2,900 per QALY 
gained vs tiotropium monotherapy. From a National Sickness 
Fund perspective, tiotropium + olodaterol is the dominant 
treatment, that is, more QALYs and less costs, compared 
with tiotropium monotherapy. In this analysis, the lifetime 
treatment medication cost was higher for tiotropium + olodat-
erol, but this was completely compensated by a reduction in 
cost for COPD exacerbations. From the societal perspective, 
the higher treatment medication costs were not completely 
compensated by the reduction in exacerbation costs, but the 
cost difference was small at +€123. The difference between 
the results from the National Sickness Fund and the soci-
etal perspectives can be explained by a smaller difference 
in medication cost between tiotropium + olodaterol and 
Figure 3 Cost-effectiveness acceptability curve for the costs per QalY gained for 
tiotropium + olodaterol (solid line) vs tiotropium monotherapy (dashed line) based 
on discounted costs from the societal perspective.
Abbreviation: QalYs, quality-adjusted life-years.
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Figure 4 sensitivity analysis on cost per QalY gained for tiotropium + olodaterol vs tiotropium monotherapy based on discounted cost from the societal perspective 
(reference ICer of the main analysis: €2,900/QalY gained).
Abbreviations: ICer, incremental cost-effectiveness ratio; ICs, inhaled corticosteroids; QalYs, quality-adjusted life-years.
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tiotropium monotherapy from the National Sickness Fund 
perspective (+€0.38 per day) compared with the societal 
perspective (+€0.59 per day) because the latter includes the 
additional costs of medication not covered by the National 
Sickness Fund (Table 2). Results were robust to changes 
in several assumptions with all performed SA resulting in 
ICERs below €20,000 per QALY gained.
Two previous studies investigated the CE of the fixed-
dose combination of olodaterol + tiotropium vs tiotropium 
monotherapy. Selya-Hammer et al reported a CE ratio of 
€7,518 per QALY gained for treatment with olodaterol + 
tiotropium using a time horizon of 15 years and the perspec-
tive of the Italian National Health Service.27 van Boven et al 
performed a CE analysis from the Dutch health care payer’s 
perspective using a 15-year time horizon and found a CE ratio 
of €7,004 per QALY gained.28 In both studies, the difference 
in effectiveness of olodaterol + tiotropium vs tiotropium 
monotherapy was modeled as an increase in trough FEV
1
 
in the first 52 weeks based on the results of the TONADO 
trial,3 but no direct reduction in exacerbations was modeled. 
As a result of the improved lung function, a slight indirect 
reduction in annual exacerbation rate was observed in both 
studies as well as a small improvement in life-expectancy. 
In the current study, a direct effect on exacerbations was 
modeled, but no direct improvement in lung function was 
included, although the current model includes a small indirect 
effect of reducing the number of moderate and severe exac-
erbations on lung function. Therefore, the CE ratios found 
in the current study are most likely conservative estimates 
as are the estimates in the previous studies.27,28
In the DYNAGITO trial, a large part of the patients was 
using ICS (70%). Post hoc analysis of the DYNAGITO trial 
showed that tiotropium + olodaterol was more effective 
compared with tiotropium monotherapy in the subgroup of 
patients using ICS at baseline, but not in non-ICS users.6 For 
the current study, we did not perform any subgroup analysis. 
The treatment effect of tiotropium + olodaterol vs tiotropium 
monotherapy, the exacerbation RR, in the model was based 
on the combined patient population of ICS and non-ICS 
users. The model outcomes are, therefore, representative of 
a population with about two-third of ICS users. This means 
that results in terms of CE found in the current study cannot 
be extrapolated to the group of COPD patients not using ICS. 
It should also be noted that the RR used to model the differ-
ence in treatment effect between tiotropium + olodaterol and 
tiotropium monotherapy was assumed constant over the total 
remaining lifetime of the patient. One of the SA showed that 
using a 5-year time horizon instead of a lifetime horizon still 
resulted in a cost per QALY gained below €10,000/QALY, so 
treatment with tiotropium + olodaterol can also be considered 
cost-effective in the short run. Discontinuation of treatment 
was also not taken into account, which was in line with the 
exacerbation RRs presented in the DYNAGITO trial that 
were based on exacerbation rates during actual treatment.
The strength of the current study is that the model used 
for the CE analysis is a very comprehensive model, includ-
ing a wide range of outcomes. Thus, besides showing the 
final results in terms of QALYs and costs, the model is also 
capable of showing the impact of reduction in exacerbations 
on annual lung function decline, exercise capacity, physical 
activity, symptoms, disease-specific quality of life, and 
remaining life-expectancy (as shown in Table 4). Another 
strength of the model is that it has been built using the com-
bined data from five large tiotropium trials, including data 
from a total number of about 35,000 patients.
A limitation of the current study is that QALYs in 
the model are not based on utility values that are directly 
measured, but based on utility values that are derived from 
SGRQ total scores using a previously published algorithm 
for the UK.25 Using a so-called mapping algorithm has 
disadvantages, because it seems to underestimate utility 
values in milder health states and overestimate values in 
more severe health states and utilities cannot be translated 
to other countries.29 This might have influenced the QALY 
calculations. However, because the large tiotropium trials 
used to build the model did not include sufficient data 
on utility values, equation-predicted utility values based 
on different patient and disease characteristics could not 
be estimated. Hence, using a mapping algorithm was the 
only possible solution to derive utilities. Regarding costs, 
the model includes COPD-related costs for a substantial 
number of healthcare services: treatment medication, GP 
and specialist visits, spirometries, influenza vaccinations, 
concomitant medication, costs for exacerbations, and costs 
of pneumonia. However, some important costs were not 
included in the model, such as costs of visits to respiratory 
nurses, costs of pulmonary rehabilitation, or cost related to 
long-term oxygen use. Because this results in an underes-
timation of total costs for both tiotropium + olodaterol and 
tiotropium monotherapy, the impact on the cost difference 
between the two treatment options was expected to be small. 
For the current study, the model was adapted to the French 
setting by including unit costs in France for all different 
types of medication and health care use. The only data 
source available to provide cost estimates for the cost of a 
moderate and severe exacerbation in France was the study 
by Laurendeau et al.16 The estimates reported in this study 
were used in other studies as well,19 and are based on the 
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French medico-administrative databases (French general 
beneficiary sample database EGB). The main disadvantage 
of using these estimates was that the estimates included 
both COPD- as well as non-COPD-related costs, while 
the model only included COPD-related costs. To test the 
impact of using the higher cost estimates for exacerbations, 
an SA was done with 34% lower cost estimates, which 
showed that the ICER remained in the range considered 
cost-effective in France.
The model used for the analyses was extensively 
validated.7 For the current study, the exacerbation rates for 
tiotropium monotherapy predicted by the model in the first 
year were compared with the rates as reported for the tiotro-
pium arm of the 1-year DYNAGITO trial.6 This validation 
exercise showed that the exacerbation rates predicted by the 
model for the first year were comparable with the observed 
exacerbations rates in the DYNAGITO trial, 0.87 vs 0.88 
for total exacerbations and 0.17 vs 0.17 for severe exacerba-
tions. For the DYNAGITO trial, the adjusted exacerbation 
rates for the tiotropium arm based on the negative binomial 
regression model were higher, namely, 0.97 for total exac-
erbations and 0.20 for severe exacerbations.6 The 1-year 
mortality rate predicted by the model was higher than that 
observed in the DYNAGITO trial, 4.6% vs 3.1%, which 
seems to indicate that the model is overestimating mortality 
somewhat.6 Because this was done for both tiotropium + 
olodaterol and tiotropium monotherapy, the impact on the 
differences between the treatment options is limited.
The model outcomes were representative for the 
group of patients that participated in the large tiotropium 
trials, that is, secondary care patients with moderate-
to-severe airflow obstruction and no life-treating other 
diseases. This is relevant because the effectiveness data 
for olodaterol + tiotropium were also based on trial data, 
that is, the DYNAGITO trial. However, it does limit the 
extrapolation of the results to the total COPD population, 
because a large proportion of COPD patients has mild-to-
moderate airflow limitation, is treated in primary care, and 
has a substantial number of comorbidities.30
Conclusion
This model-based analysis showed that on the basis of the 
results of a large and robust exacerbation trial, the fixed-dose 
combination of tiotropium + olodaterol is the dominant treat-
ment option, that is, providing more QALYs for less costs, 
compared with tiotropium monotherapy from the French 
National Sickness Fund perspective. From the societal 
perspective, tiotropium + olodaterol can be considered a 
cost-effective therapeutic option compared with tiotropium 
monotherapy. This finding was consistent across all SA that 
were conducted.
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